The Lein lab is focused on developing therapeutic strategies for protecting the brain from the neurodegenerative effects associated with chemical-induced life-threatening seizures (status epilepticus).
This research is part of the UC Davis CounterACT Center of Excellence, which coordinates the development of more effective medical countermeasures to treat individuals acutely intoxicated with chemical threat agents, such as organophosphates, that trigger seizures. As part of this work, we are collaborating with the Center for Molecular and Genomic Imaging (hyperlink to CMGI) to develop quantitative MRI and PET tracers for longitudinally tracking neuropathology and therapeutic effects of candidate countermeasures in rodent models. This work is a collaborative effort with the laboratories of Michael Rogawski, Isaac Pessah, Heike Wulff, Bruce Hammock, Daniel Tancredi, Abhijit Chaudhari, Joel Garbow, Jill Silverman, Danielle Harvey].
Novel Anticonvulsant and Neuroprotective Therapies for TETS and OP Intoxication
U54 NS079202 Lein (PI) 09/01/2012 - 08/31/2022
The unifying goal of the UC Davis CounterACT Center of Excellence is to identify improved medical countermeasures for treating acute intoxication with seizure-inducing chemical threat agents.
Identifying Molecular Targets for the Proconvulsant Activity of TETS
R21 NS110647 Lein (Contact) and Wulff (MPI) 07/01/2019 - 06/30/2021
The goal of this project is to test the central hypothesis that α2β3γ2 receptors, which are far more abundant in the mammalian CNS than α6β3γ2 receptors, constitute the major molecular target of TETS and, based on the structural similarity between the two compounds, also of RDX.